Prefilled Syringe CMC — Device-Drug Combination Regulatory Strategy Under 21 CFR Part 3 Combination Products

The prefilled syringe is simultaneously a container closure system and a drug delivery device. How you define it in your NDA determines the entire CMC regulatory pathway.

As a container closure system, the requirements are 2.3.P.2 qualification data, extractables and leachables, and container closure integrity. As a combination product, all of that still applies, plus a device constituent part package, a design history file summary, ISO 11040 device testing, human factors summative usability studies, and 21 CFR Part 820 device quality system compliance. The designation isn’t a sponsor’s to make unilaterally, FDA’s Office of Combination Products decides. The real question is whether OCP was engaged before filing, or whether the answer arrives in a Major Deficiency letter a year after submission.

CCS vs. Combination Product — The 21 CFR Part 3 Designation Decision, the OCP RFD Process, and the Pre-Filing Clarity That Prevents Post-Submission Reclassification

The distinction between a prefilled syringe treated as a container closure system and one treated as a genuine combination product traces back to the primary mode of action test under 21 CFR Part 3. A syringe that passively contains and delivers the drug, no electronic component, no needle safety mechanism affecting dose delivery, is typically classified as a drug product with a container closure system, not a combination product. A syringe with an integrated safety device, a needle guard or autoinjector mechanism that genuinely contributes to reliable dose delivery, can carry a device constituent significant enough to trigger combination product designation instead. The Request for Designation process exists specifically to resolve this question formally: submission to FDA’s Office of Combination Products, with a designation decision generally issued within 60 days establishing which center, CDER, CDRH, or CBER, holds primary jurisdiction. The practical guidance here is straightforward: submit an RFD before NDA filing, not after, whenever the PFS carries an integrated safety device, whenever marketing materials describe the syringe as a delivery device rather than packaging, or whenever the instructions for use are as clinically critical to safe administration as the drug label itself. Getting that designation locked in before filing eliminates the single most disruptive risk in this domain, a mid-review reclassification that suddenly requires device constituent part documentation nobody built into the original submission timeline.

Human Factors Summative Usability Testing for PFS — Final Commercial Device Requirement, Critical Task Design, Participant Numbers, and the Major Deficiency Risk of Non-Final Device Testing

The summative usability study is the definitive validation step for a PFS combination product’s human factors package, and its design has to reflect every intended user population, trained healthcare providers, lay patients, and caregivers, depending on the actual administration setting, with a recommended minimum of 15 participants per distinct user group, commonly expanded to 30 for lay-user populations given their greater variability. The requirement that generates the most costly failures if missed is simulated-use fidelity: the study has to run with the final commercial device in every physical and functional respect, the actual commercial syringe barrel, plunger, rigid needle shield, backstop, label, and instructions for use, not a prototype or an earlier device iteration that differs in any of those respects. Critical tasks need to be pre-specified before the study runs, typically covering needle cap removal without contamination, any required air bubble removal step, correct injection technique and depth confirmation, full plunger depression to complete dose delivery, and post-injection needle safety activation, with the primary endpoint generally expressed as zero critical use errors across the primary fifteen-participant analysis set. A summative study conducted with a device configuration that differs from what’s actually going to market, a different needle safety mechanism, different backstop color coding, an instructions-for-use draft that doesn’t match the final commercial label, isn’t a minor documentation mismatch, it’s the single most common trigger for a Major Deficiency in this domain, and the remedy isn’t a supplemental analysis, it’s an entirely new summative study with the actual commercial device, adding well over a year to the approval timeline in many cases.

PFS Device Constituent Part Siliconization, E&L, and ISO 11040-4 Functional Testing — Specification Design for the Three CMC Parameters FDA Reviewers Examine Most Closely

Siliconization of the glass barrel’s inner surface, generally in the range of 0.3 to 0.8 mg of silicone per barrel for a standard 1 mL long prefilled syringe, is what actually makes the plunger move smoothly enough for reliable subcutaneous self-injection, and ISO 11040-4 sets the functional benchmarks directly: break-loose force at or below 20 N, the force needed to initiate plunger movement from rest, and glide force at or below 15 N, the force needed to sustain movement through the injection. Under-siliconization pushes break-loose force above that threshold, risking a genuine critical use error where a patient’s thumb force simply isn’t sufficient to start the injection at all, while over-siliconization introduces its own real risk, migrating silicone oil droplets into the formulation that can nucleate protein aggregation for monoclonal antibody and biologic products, directly threatening compliance with the standard subvisible particle limit of 6,000 particles per mL at 10 μm and above. Both failure modes make clear that siliconization has to be verified on the actual filled, commercial drug product across the stability program, not confirmed once on the empty pre-fill barrel and assumed stable thereafter. The device constituent part’s extractables and leachables program carries its own added complexity beyond a standard vial stopper study: the rigid needle shield sits in direct contact with the stainless steel needle itself, creating a concentrated interface where metal leachables, nickel and chromium specifically, can migrate at higher rates than the bulk container closure system would suggest, making targeted ICP-MS analysis against the relevant ICH Q3D parenteral permitted daily exposures a genuinely necessary addition to the standard three-solvent extractables protocol rather than an optional supplement.

The XGene Prefilled Syringe Combination Product CMC Architecture — Designation Strategy, Device Testing, Human Factors Program, E&L, and NDA/BLA Documentation Structure

The XGene Prefilled Syringe Combination Product CMC Architecture is a structured PFS drug-device CMC development and regulatory documentation framework built around resolving the container-closure-versus-combination-product question before it becomes a mid-review surprise.

1. Combination Product Designation Strategy — Assess the syringe’s actual mode of action against 21 CFR Part 3’s primary mode of action test, and submit an RFD to OCP proactively whenever a safety device, marketing description, or IFU criticality suggests combination product status. 2. PFS Device Constituent Part Qualification — Validate break-loose and glide force against ISO 11040-4, confirm siliconization on the actual filled drug product across stability, and build a targeted metal leachables program for the needle-shield interface. 3. Human Factors Engineering Program Design — Run formative usability studies during device design, then a summative study using the exact final commercial configuration with pre-specified critical tasks and adequate participant numbers per user group. 4. Device Constituent Part Documentation — Assemble the design history file summary, device master record summary, and human factors engineering report to FDA’s expected format before filing. 5. NDA/BLA Module 3 Documentation Structure — Integrate the container closure or device constituent qualification, drug-device compatibility data, and any combination product addendum into a single coherent Module 3 package matched to the confirmed OCP designation.

The output is the PFS CMC strategy that resolves designation, device testing, and human factors requirements before filing, rather than discovering the combination product classification and its full documentation burden through review-stage correspondence.

21 CFR Part 3 establishes the combination product designation framework and primary mode of action test this article’s analysis is built around. FDA’s Guidance for Industry and FDA Staff: Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development (2016) and FDA’s complementary Human Factors Engineering guidance (2016) establish the summative usability study design and final-commercial-device requirement. ISO 11040-4 establishes the break-loose and glide force functional performance standard for prefilled syringes, and FDA’s Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics (1999) establishes the underlying CCS qualification requirement applicable when the container-closure approach, rather than combination product designation, governs the filing.

For your prefilled syringe injectable NDA or BLA CMC package, can you confirm today that you have obtained or initiated a formal combination product designation from FDA’s Office of Combination Products before filing, that your summative usability study uses the final commercial PFS configuration with adequate participants per distinct user group, and that your siliconization specification includes break-loose and glide force testing per ISO 11040-4 alongside a drug product protein aggregation compatibility dataset?